Jacqueline Brown
- Department of Hematology and Medical Oncology
Assistant Professor
- (404) 778-0605
- jacqueline.theresa.brown@emory.edu
Academic Appointment
- Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from University of Rochester
Research
Publications
-
Challenges and opportunities in the management of non-urothelial bladder cancers.
Cancer Treat Res Commun Volume: 34 Page(s): 100663
01/01/2023 Authors: Brown JT; Narayan VM; Joshi SS; Harik L; Jani AB; Bilen MA -
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.
J Immunother Precis Oncol Volume: 5 Page(s): 52 - 57
08/01/2022 Authors: Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Hitron EE; Russler GA; Yantorni L; Caulfield S; Brown JT -
Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
Cancers (Basel) Volume: 14
06/10/2022 Authors: Zhuang TZ; Case K; Olsen TA; Brown JT; Carthon BC; Kucuk O; Goldman J; Harris W; Bilen MA; Nazha B -
Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
Oncologist Volume: 27 Page(s): 462 - 468
06/08/2022 Authors: Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA -
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Clin Genitourin Cancer Volume: 20 Page(s): 53 - 59
02/01/2022 Authors: Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S -
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy.
Front Endocrinol (Lausanne) Volume: 13 Page(s): 779915
01/01/2022 Authors: Olsen TA; Zhuang TZ; Caulfield S; Martini DJ; Brown JT; Carthon BC; Kucuk O; Harris W; Bilen MA; Nazha B -
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case report.
Front Oncol Volume: 12 Page(s): 949400
01/01/2022 Authors: Zhuang TZ; Harik L; Force S; Hadadi A; Bilen MA; Brown JT; Carthon BC; Goldman J; Kucuk O; Master VA -
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Oncologist Volume: 26 Page(s): 1017 - 1025
12/01/2021 Authors: Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L -
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Oncologist Volume: 26 Page(s): 956 - 964
11/01/2021 Authors: Smith KER; Brown JT; Wan L; Liu Y; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O -
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist Volume: 26 Page(s): e1742 - e1750
10/01/2021 Authors: Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA